Redhill Biopharma (RDHL) PT Raised to $30 at Roth Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
RedHill Biopharma (RDHL) Announces RHB-105 Phase 3 Met Primary Endpoint as H. Pylori Treatment
June 15, 2015 6:06 AM EDTRedHill Biopharma (Nasdaq: RDHL) announced positive top-line results from its Phase III study with RHB-105 for the treatment of Helicobacter pylori (H. pylori) bacterial infection. Top-line results from the study demonstrated 89.4% efficacy in eradicating H. pylori infection with... More
